NCT02349503View on ClinicalTrials.gov

Safety, Pharmacokinetics and Pharmacodynamics of NBI-77860 in Adolescent Females With Congenital Adrenal Hyperplasia

PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

February 28, 2015

Primary Completion Date

October 31, 2015

Study Completion Date

October 31, 2015

Conditions
Congenital Adrenal Hyperplasia
Interventions
DRUG

NBI-77860

DRUG

NBI-77860

DRUG

NBI-77860

Trial Locations (2)

48109

Ann Arbor

98105

Seattle

Sponsors
All Listed Sponsors
lead

Neurocrine Biosciences

INDUSTRY